

REMARKS/ARGUMENTS

Restriction Requirement

The Examiner has required restriction to one of the following inventions:

Group I Claims 1-8, drawn to an isolated nucleic acid, a vector containing same, a host cell thereof, and a method of recombinantly producing the encoded polypeptide.

Group II Claims 9-11 and 14-17 in part, drawn to an isolated polypeptide, a chimeric molecule thereof, an agonist thereof, and a composition and an article thereof.

Group III Claims 12, 13, and 14-17 in part, drawn to an antibody to the polypeptide, and a composition and an article thereof.

Group IV Claims 14-17, drawn to an antagonist of the polypeptide, and a composition and an article thereof.

Group V Claim 18 in part, drawn to a method of treating psoriasis by administering the polypeptide.

Group VI Claim 18 in part, drawn to a method of treating psoriasis by administering an antagonist of the polypeptide.

Group VII Claim 18 in part, drawn to a method of treating psoriasis by administering an antibody of the polypeptide.

Group VIII Claims 19 and 21, drawn to a method of determining the presence of a PRO polypeptide in a sample, and a method of diagnosing psoriasis with an antibody.

Group IX Claim 20, drawn to a method of diagnosing psoriasis by detecting the level of expression of a gene encoding the polypeptide.

Group X Claim 22, drawn to a method of identifying a compound inhibiting the activity of the polypeptide.

Group XI Claims 23 and 24, drawn to a method of identifying a compound inhibiting the expression of a gene encoding the polypeptide, wherein said candidate compound is an anti-sense nucleic acid.

Group XII Claim 25, drawn to a method of identifying a compound mimicking the activity of the polypeptide.

The Examiner has also required that a SEQ ID NO: be elected.

Applicants elect Group III, Claims 12, 13, and 14-17 in part, drawn to an antibody to the polypeptide, and a composition and an article thereof. Applicants further elect SEQ ID NO:14 (PRO2874), which is encoded by SEQ ID NO:13 (DNA327522) for the elected claims.


CONCLUSION

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned agent at the telephone number shown below.

Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39766-0263 R1). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully Submitted,

Date: November 13, 2007

By: 
Panpan Gao (Reg. No. 43,626)

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, California 94025
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

SV 2315880 v1
(39766.0263)